A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Jason FangusaroArzu Onar-ThomasTina Young PoussaintShengjie WuAzra H LigonNeal LindemanOlivia CampagneAnu BanerjeeSridharan GururanganLindsay B KilburnStewart GoldmanIbrahim QaddoumiPatricia BaxterGilbert VezinaCorey BregmanZoltan PatayJeremy Y JonesClinton F StewartMichael J FisherLaurence Austin DoyleMalcolm SmithIra J DunkelMaryam Fouladi

Published in: Neuro-oncology (2021)

Selumetinib was tolerable and led to responses and prolonged disease stability in children with recurrent/progressive OPHGs based upon radiographic response, PFS, and visual outcomes.

Keyphrases

low grade
young adults
high grade
multiple sclerosis
signaling pathway
oxidative stress
randomized controlled trial
type diabetes
cell proliferation
skeletal muscle
nuclear factor
glycemic control